18F-FDG and 11C-methionine PET for evaluation of treatment response of lung cancer after stereotactic radiotherapy

Ann Nucl Med. 2004 Dec;18(8):669-74. doi: 10.1007/BF02985960.

Abstract

This study was performed to investigate the feasibility of FDG- and L-[methyl-11C]methionine (Met)-PET for the follow up of lung cancer after stereotactic radiotherapy (SRT). Nine patients (pt) with solitary lung cancer underwent SRT. Met- and FDG-PET studies were performed one week before SRT and from one week to 8 months after SRT. Responses to SRT were complete in 2 pt and partial in 7 pt. Met- and FDG-PET scan showed high tracer uptake in all tumors before SRT. After SRT, standardized uptake values (SUV) of FDG and Met changed concordantly. Both decreased with time in 5 pt but did not decrease steadily in 4 pt, where 2 pt showed an increase at 1 to 2 weeks after SRT and 2 pt showed an increase at more than 3 months after SRT. The former appears to reflect the acute reaction to SRT and the latter radiation-induced pneumonitis. Although the addition of Met-PET did not provide additional information over FDG-PET, FDG- and Met-PET could be used to evaluate the treatment effect of SRT.

Publication types

  • Clinical Trial

MeSH terms

  • Aged
  • Aged, 80 and over
  • Female
  • Fluorodeoxyglucose F18*
  • Humans
  • Image Enhancement / methods
  • Lung Neoplasms / diagnostic imaging
  • Lung Neoplasms / surgery
  • Male
  • Methionine*
  • Middle Aged
  • Positron-Emission Tomography / methods*
  • Prognosis
  • Radiopharmaceuticals
  • Radiosurgery / methods*
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Solitary Pulmonary Nodule / diagnostic imaging*
  • Solitary Pulmonary Nodule / surgery*
  • Treatment Outcome

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18
  • carbon-11 methionine
  • Methionine